RxDoctor Payments Data

Smruti Nalawadi, MD

Internal Medicine · Morgan Hill, CANPI 1972767655

Payments from drug & device makers

$1,423in general payments, 2019–2025

Across 91 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$352
  • Novo Nordisk$299
  • Currax Pharmaceuticals LLC$202
  • AstraZeneca$121
  • Johnson & Johnson$117
  • Mylan Specialty L.p.$70
  • plus $261 from 11 others

What the payments were for

  • Food & beverage$1,39898%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,423 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$220,638
Medicare patients
288
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$85,632
MounjaroTirzepatide51$78,729
FarxigaDapagliflozin Propanediol69$77,188
OzempicSemaglutide53$57,447
RybelsusSemaglutide22$32,627
DapagliflozinDapagliflozin Propanediol29$14,949
LinzessLinaclotide12$14,807
EliquisApixaban21$13,880
GemtesaVibegron15$12,723
MyrbetriqMirabegron11$10,390
Pantoprazole Sodium129$5,174
Montelukast Sodium162$3,392
Atorvastatin Calcium282$3,387
Rosuvastatin Calcium155$3,153
Levothyroxine Sodium298$3,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$299$90,07475 claims
Boehringer IngelheimJardiance$19$85,63266 claims
Lilly USA, LLCMounjaro$24$78,72951 claims
AstraZenecaFarxiga$121$77,18869 claims
AbbVieLinzess, Synthroid$352$17,49138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Morgan Hill

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →